Effectiveness of an Impella Versus Intra‐Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation
Authors:
- Yuji NishimotoYNYuji Nishimoto
- Hiroyuki OhbeHOHiroyuki Ohbe
- Toru TakiguchiTTToru Takiguchi
- Mikio NakajimaMNMikio Nakajima
- Toshiaki IsogaiTIToshiaki Isogai
- Hiroki MatsuiHMHiroki Matsui
- Yukihito SatoYSYukihito Sato
- Tetsuya WatanabeTWTetsuya Watanabe
- Takahisa YamadaTYTakahisa Yamada
- Masatake FukunamiMFMasatake Fukunami
Open Access
- 4 February 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037652
Abstract
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Current issues of destination therapy in Japan: to achieve 5−year or even longer survivalJournal of Artificial Organs, 2024
- Venting during venoarterial extracorporeal membrane oxygenationClinical Research in Cardiology, 2022
- Public Assistance in Patients with Acute Heart Failure: A Report from the KCHF RegistryESC Heart Failure, 2022
- Rates and impact of vascular complications in mechanical circulatory supportCatheterization and Cardiovascular Interventions, 2022
- Development and validation of a procedure‐based organ failure assessment model for patients in the intensive care unit: an administrative database studyAcute Medicine & Surgery, 2021
- Total percutaneous biventricular assist device implantation for fulminant myocarditisJournal of Artificial Organs, 2020
- The second official report from Japanese registry for mechanical assisted circulatory support (J-MACS): first results of bridge to bridge strategyGeneral Thoracic and Cardiovascular Surgery, 2019
- SCAI clinical expert consensus statement on the classification of cardiogenic shockCatheterization and Cardiovascular Interventions, 2019
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003Statistics in Medicine, 2007